TKT and acute myeloid leukemia: FLT3-ITD occurs in approximately 25% of AML patients and the mutated gene encodes a mutant receptor with aberrant, ligand-independent tyrosine kinase (TK) activity that confers growth and survival advantages to leukemic blasts [9].